13+ hour, 29+ min ago  (335+ words) Can-Fite has reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients achieved its primary safety endpoint. The open-label study also showed durable overall survival outcomes. It enrolled 20 advanced pancreatic ductal adenocarcinoma patients who had progressed…...

11+ hour, 26+ min ago  (269+ words) Astra Zeneca has signed a strategic collaboration agreement with'Abbisko Therapeutics to study the combined use of Tagrisso (osimertinib) and lumipodlin (ABSK043) in patients with non-small cell lung cancer (NSCLC). The multicentre, open-label Phase I/II trial will assess the safety and…...

10+ hour, 41+ min ago  (409+ words) Divarasib outperformed existing therapies in patients with KRAS G12 C non-small cell lung cancer (NSCLC). Roche-owned Genentech's KRAS G12 C inhibitor, divarasib, has outperformed marketed drugs in its class in a Phase III head-to-head study " a result the company says could put…...

1+ day, 7+ hour ago  (343+ words) In the Baby-COMET trial, Nexviazyme met all primary and secondary endpoints, teeing it up for potential label expansion. Sanofi's Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase III Baby-COMET trial met…...

1+ day, 8+ hour ago  (545+ words) Clinical Trials Arena Abb Vie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which was presented on 29 June at the 12th Congress of the European Academy of Neurology (EAN) 2026, supported the safety…...

1+ day, 11+ hour ago  (336+ words) The IGNITE network connects trial sponsors with research sites aligned to Allucent's therapeutic centres of expertise. Allucent has introduced the Integrated Global Network for Innovative Trial Execution (IGNITE) aimed at improving speed, quality as well as predictability across clinical trial…...

1+ day, 10+ hour ago  (255+ words) This further weakens Amgen's case for Tavneos' continued use on the market as the drug comes under intense regulatory scrutiny. In another blow to the future market prospects of Amgen's rare disease therapy, Tavneos (avacopan), the New England Journal of…...

1+ day, 10+ hour ago  (652+ words) Clinical Trials Arena On June 29, at the 12th Congress of the European Academy of Neurology (EAN) 2026, Neuro Derm presented post hoc analysis from the pivotal Phase III Bou NDless (NCT04006210) study. The presentation highlighted findings supporting Onerji (ND0612), a continuous 24-hour subcutaneous infusion…...

1+ day, 12+ hour ago  (419+ words) Topline results from RISE3 are expected in H2 2026. Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7. 2/7. 3 channel activator, opakalim (BHV-7000), for refractory focal epilepsy. Topline data from the double-blind, randomised, placebo-controlled trial is expected in the…...

2+ day, 4+ hour ago  (419+ words) Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL. Genmab's Phase III trial of a combination therapy including its bispecific T-cell engager (Bi TE) combination, including Epkinly, has met its primary…...